---
title: 'T-Cell Lymphomas in Recipients of CAR-T Cells: Assessing Risks and Causalities'
date: '2024-10-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39393068/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241011200419&v=2.18.0.post9+e462414
source: Blood
description: The United States Food and Drug Administration (FDA) announcement in
  November 2023 regarding reports of the occurrence of secondary T-cell lymphomas
  in patients receiving chimeric antigen receptor T-cells (CAR-T) for B-cell malignancies
  resulted in widespread concern among patients, clinicians and scientists. Little
  information relevant to assessing causality, most importantly whether CAR retroviral
  or lentiviral vector genomic insertions contribute to oncogenesis, was initially
  ...
disable_comments: true
---
The United States Food and Drug Administration (FDA) announcement in November 2023 regarding reports of the occurrence of secondary T-cell lymphomas in patients receiving chimeric antigen receptor T-cells (CAR-T) for B-cell malignancies resulted in widespread concern among patients, clinicians and scientists. Little information relevant to assessing causality, most importantly whether CAR retroviral or lentiviral vector genomic insertions contribute to oncogenesis, was initially ...